FOMX / Foamix Pharmaceuticals Ltd. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

FOMX / Foamix Pharmaceuticals Ltd. 15-12B - - FORM 15-12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36621 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specifie

FOMX / Foamix Pharmaceuticals Ltd. S-8 POS - - S-8 POS

As Filed with the Securities and Exchange Commission on March 18, 2020 Registration No.

FOMX / Foamix Pharmaceuticals Ltd. S-8 POS - - S-8 POS

S-8 POS 1 a20-120655s8pos.htm S-8 POS As Filed with the Securities and Exchange Commission on March 18, 2020 Registration No. 333-209403 Registration No. 333-215498 Registration No. 333-222155 Registration No. 333-230942 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-209403 FORM S-8 REGISTRATION STATEMENT NO. 333-

FOMX / Foamix Pharmaceuticals Ltd. S-8 POS - - S-8 POS

As Filed with the Securities and Exchange Commission on March 18, 2020 Registration No.

FOMX / Foamix Pharmaceuticals Ltd. POS AM - - POS AM

As Filed with the Securities and Exchange Commission on March 18, 2020 Registration No.

FOMX / Foamix Pharmaceuticals Ltd. S-8 POS - - S-8 POS

As Filed with the Securities and Exchange Commission on March 18, 2020 Registration No.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File

Contract Manufacturing and Supply Agreement, dated October 21, 2019, by and between Foamix Pharmaceuticals Ltd. and ASM Aerosol-Service AG (incorporated by reference to Exhibit 10.26 of Foamix Pharmaceuticals Ltd.’s Annual Report on Form 10-K filed on March 12, 2020).

Exhibit 10.26 CONTRACT MANUFACTURING AND SUPPLY AGREEMENT FOAMIX PHARMACEUTICALS LTD. ASM AEROSOL-SERVICE AG Table of Contents Page PREAMBLE 1 1. DEFINITIONS 1 2. COMMENCEMENT AND TERM 4 3. AGREEMENT TO SUPPLY 5 4. MANUFACTURE 5 5. COMMUNICATION AND AUTHORITY REQUESTS 6 6. SUPPLY OF FOAMIX API MATERIAL AND OTHER PRODUCT MATERIAL 6 7. FORECASTS, PURCHASE ORDERS AND CAPACITY 8 8. DELIVERY AND LATE D

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36621 Foamix Pharmace

List of Subsidiaries of Foamix Pharmaceuticals Ltd.

EX-21.1 4 exhibit21-1.htm EXHIBIT 21.1 Exhibit 21.1 Foamix Pharmaceuticals Ltd. The following is a list of subsidiaries of Foamix Pharmaceutical Ltd. as of December 31, 2019: SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Foamix Pharmaceutical Inc. Delaware

Description of Securities Registered Under Section 12 of the Exchange Act

Exhibit 4.2 FOAMIX PHARMACEUTICALS LTD. DESCRIPTION OF ORDINARY SHARES As of December 31, 2019 As of December 31, 2019, the ordinary shares, par value NIS 0.16 per share, (the “Ordinary Shares”) of Foamix Pharmaceuticals Ltd. (“Foamix”) were listed on the Nasdaq Global Stock Market (“Nasdaq”) under the symbol “FOMX.” As of March 9, 2020, all Ordinary Shares are owned by Menlo Therapeutics Inc. and

Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019

Exhibit 99.1 Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019 Foamix Became a Wholly Owned Subsidiary of Menlo Therapeutics Upon Closing of Merger on March 9, 2020 Menlo Conference Call and Webcast Scheduled for Thursday, March 12th at 8:30am Eastern Time BRIDGEWATER, N.J., March 12, 2020 - Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2020 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) Israel (State or other jurisdiction of incorporation) 001-36621 (Commission File Number) N/A

Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Exhibit 99.1 Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications BRIDGEWATER, N.J., March 9, 2020 – Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix

Articles of Association of Foamix Pharmaceuticals Ltd.

Exhibit 3.1 The Companies Law, 5759-1999 Amended and Restated Articles of Association of FOAMIX PHARMACEUTICALS LTD. (the “Company”) 1. Definitions 1.1. Capitalized terms used in these Articles of Association (the “Articles”) shall bear the meanings ascribed to such terms as set forth in this Article, unless inconsistent with the context: The “Company” – as defined in Paragraph 2 of these Articles

FOMX / Foamix Pharmaceuticals Ltd. 425 - Merger Prospectus - 425

Filed by Foamix Pharmaceuticals Ltd. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule l4a-12 under the Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No.: 001-36621 Form S-4 filed by Menlo Therapeutics Inc. File No.: 333-235351 Investor Presentation|March 2020 A Proposed Compelling Dermatology Combination Forward-Looking Sta

AGREEMENT

EX-99.1 2 d863197dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2

FOMX / Foamix Pharmaceuticals Ltd. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d863197dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Foamix Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.16 per share (Title of Class of Securities) M46135105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Sta

FOMX / Foamix Pharmaceuticals Ltd. / Orbimed Capital Llc Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

FOMX / Foamix Pharmaceuticals Ltd. / GREAT POINT PARTNERS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

Foamix and Menlo Announce Shareholder Approval of Proposed Merger Transaction on Track to Close in early March 2020

Exhibit 99.1 Foamix and Menlo Announce Shareholder Approval of Proposed Merger Transaction on Track to Close in early March 2020 REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, C.A., February 6, 2020 – Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2020 Menlo Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commis

Foamix and Menlo Announce Shareholder Approval of Proposed Merger Transaction on Track to Close in early March 2020

Exhibit 99.1 Foamix and Menlo Announce Shareholder Approval of Proposed Merger Transaction on Track to Close in early March 2020 REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, C.A., February 6, 2020 – Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder

FOMX / Foamix Pharmaceuticals Ltd. 425 - Merger Prospectus - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2020 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission Fil

Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2020 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission Fil

Foamix and Menlo Announce Shareholder Approval of Proposed Merger Transaction on Track to Close in early March 2020

EX-99.1 Exhibit 99.1 Foamix and Menlo Announce Shareholder Approval of Proposed Merger Transaction on Track to Close in early March 2020 REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, C.A., February 6, 2020 – Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all sha

FOMX / Foamix Pharmaceuticals Ltd. 425 - Merger Prospectus - 425

Filed by Foamix Pharmaceuticals Ltd. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule l4a-12 under the Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No.: 001-36621 Form S-4 filed by Menlo Therapeutics Inc. File No.: 333-235351 [Dear Employee Shareholder], As a shareholder of the company as of January 6, 2020, you are entitl

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 21, 2020 Menlo Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commis

FOMX / Foamix Pharmaceuticals Ltd. DEFA14A - - DEFA14A

DEFA14A 1 d875215ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

FOMX / Foamix Pharmaceuticals Ltd. 425 - Merger Prospectus - 425

Filed by Foamix Pharmaceuticals Ltd. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No.: 001-36621 Form S-4 filed by Menlo Therapeutics Inc. File No.: 333-235351 Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics REHOVOT, Israel, and BRIDGEWA

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 425

425 Filed by Menlo Therapeutics Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No. 001-36621 [Name] [Date] Hi [Name], As you know, on November 10, 2019, Menlo Therapeutics Inc. (the “Company” or “Menlo” or “we” or “us”) and Foamix Pharmaceutica

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 425

425 Filed by Menlo Therapeutics Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No. 001-36621 Menlo Tx Letterhead Date BY [HAND/EMAIL/ETC] Name Dear (Name) Re: Retention Bonus As you know, on November 10, 2019, Menlo Therapeutics Inc. (the “Comp

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 7, 2020 Menlo Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commiss

FOMX / Foamix Pharmaceuticals Ltd. / Delaware Street Capital Master Fund, L.P. - SC 13G/A Passive Investment

SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Rule 13d-102) Amendment No.

Foamix Announces AMZEEQTM (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S. Preferred Coverage Effective Immediately on Express Scripts National Prefer

Exhibit 99.1 Foamix Announces AMZEEQTM (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S. Preferred Coverage Effective Immediately on Express Scripts National Preferred, Flex, and Basic Formularies AMZEEQ is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acn

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2020 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission Fil

FOMX / Foamix Pharmaceuticals Ltd. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

FOMX / Foamix Pharmaceuticals Ltd. 425 - Merger Prospectus - 425

Filed by Foamix Pharmaceuticals Ltd. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule l4a-12 under the Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No.: 001-36621 Form S-4 filed by Menlo Therapeutics Inc. File No.: 333-235351 Investor Presentation January 2020 A Proposed Compelling Dermatology Combination Forward-Looking S

Financial Statements and Exhibits, Other Events

8-K 1 tm201645d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of

Foamix Announces AMZEEQTM (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne AMZEEQ is the First FDA Approved Topical Form of Minocycline and the Company’s First Commercial Launc

Exhibit 99.1 Foamix Announces AMZEEQTM (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne AMZEEQ is the First FDA Approved Topical Form of Minocycline and the Company’s First Commercial Launch AMZEEQ Offers Efficacy with Low Systemic Absorption List price of $485 Competitive Against Current Acne Market Leaders REHOVOT, Israel

FOMX / Foamix Pharmaceuticals Ltd. DEFM14A - - DEFM14A

DEFM14A 1 d834396ddefm14a.htm DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as

FOMX / Foamix Pharmaceuticals Ltd. 425 - Merger Prospectus - 425

Filed by Foamix Pharmaceuticals Ltd. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No.: 001-36621 Form S-4 filed by Menlo Therapeutics Inc. File No.: 333-235351 A Proposed Compelling Dermatology Combination Investor Presentation | December 2019 Forward - Look

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 425

425 Filed by Menlo Therapeutics Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No. 001-36621 Investor Presentation | December 20, 2019 A Compelling Dermatology Combination Forward-Looking Statements This presentation contains forward-looking st

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission Fi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2019 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) Israel (State or other jurisdiction of incorporation) 001-36621 (Commission File Number)

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 16, 2019 Menlo Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commi

FOMX / Foamix Pharmaceuticals Ltd. 425 - Merger Prospectus - FORM 8-K

425 1 tm1926305-28k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2019 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) Israel (State or other jurisdiction of incorporation) 00

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 425

425 Filed by Menlo Therapeutics Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No. 001-36621 CONFIDENTIAL Employee All Hands Meeting December 9, 2019 Tax and Legal Advice Disclaimer CONFIDENTIAL Menlo does not provide tax, legal or accounting a

Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, by and among Menlo Therapeutics Inc., Giants Merger Subsidiary Ltd. and Foamix Pharmaceuticals Ltd.

EX-2.1 Exhibit 2.1 AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER This Amendment No. 1 (this “Amendment”) to the Agreement and Plan of Merger (the “Merger Agreement”) is made and entered into as of December 4, 2019 by and among Menlo Therapeutics Inc., a Delaware corporation (“Menlo”), Giants Merger Subsidiary, Ltd., a company incorporated under the laws of the State of Israel and registered

FOMX / Foamix Pharmaceuticals Ltd. 425 - Merger Prospectus - FORM 8-K

425 1 tm1924520d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2019 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) Israel (State or other jurisdiction of incorporation) 001

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2019 Menlo Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commissio

Exhibit 2.1

Exhibit 2.1 AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER This Amendment No. 1 (this “Amendment”) to the Agreement and Plan of Merger (the “Merger Agreement”) is made and entered into as of December 4, 2019 by and among Menlo Therapeutics Inc., a Delaware corporation (“Menlo”), Giants Merger Subsidiary, Ltd., a company incorporated under the laws of the State of Israel and registered under N

Exhibit 2.1

Exhibit 2.1 AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER This Amendment No. 1 (this “Amendment”) to the Agreement and Plan of Merger (the “Merger Agreement”) is made and entered into as of December 4, 2019 by and among Menlo Therapeutics Inc., a Delaware corporation (“Menlo”), Giants Merger Subsidiary, Ltd., a company incorporated under the laws of the State of Israel and registered under N

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2019 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) Israel (State or other jurisdiction of incorporation) 001-36621 (Commission File Number) N

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 425

425 Filed by Menlo Therapeutics Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No. 001-36621 [Name] [Date] Hi [NAME], As you know, on November 11, 2019, Menlo Therapeutics Inc. (the “Company” or “Menlo” or “we” or “us”) and Foamix Pharmaceutica

FOMX / Foamix Pharmaceuticals Ltd. 425 - Merger Prospectus - 425

Filed by Foamix Pharmaceuticals Ltd. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No.: 001-36621 November 14, 2019 Dear Foamix Employees: As you know, earlier this week, on November 11, 2019, Menlo Therapeutics Inc. (“Menlo”) and Foamix Pharmaceuticals Ltd.

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 425

425 Filed by Menlo Therapeutics Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No. 001-36621 This filing relates to the proposed merger of Foamix Pharmaceuticals Ltd., a company incorporated under the laws of the State of Israel (“Foamix”), wit

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 425

425 Filed by Menlo Therapeutics Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No. 001-36621 This filing relates to the proposed merger of Foamix Pharmaceuticals Ltd., a company incorporated under the laws of the State of Israel (“Foamix”), wit

FOMX / Foamix Pharmaceuticals Ltd. 425 - Merger Prospectus - FORM 425

Filed by Foamix Pharmaceuticals Ltd. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Foamix Pharmaceuticals Ltd. Commission File No.: 001-36621 Foamix Pharmaceuticals Inc. Foamix Pharmaceuticals and Menlo Therapeutics Merger Call November 11, 2019 Foamix Pharmaceuticals Inc. – Foamix Pharmaceuticals and

Transaction Highlights Strategic combination expected to create a scaled player in the dermatological space with enhanced financial profile Merger creating a stronger dermatology focused company Enhances the combined company’s late stage pipeline and

EX-99.1 Investor Presentation | November 11, 2019 A Compelling Dermatology Combination Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Words suc

Agreement and Plan of Merger, dated as of November 10, 2019, by and among Menlo Therapeutics Inc., Giants Merger Subsidiary Ltd. and Foamix Pharmaceuticals Ltd.*

EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG MENLO THERAPEUTICS INC. GIANTS MERGER SUBSIDIARY LTD. AND FOAMIX PHARMACEUTICALS LTD. DATED AS OF NOVEMBER 10, 2019 TABLE OF CONTENTS PAGE ARTICLE I THE MERGER Section 1.1 The Merger 2 Section 1.2 Closing; Effective Time 2 Section 1.3 Effect of the Merger 3 Section 1.4 Organizational Documents of Surviving Company 3 Sec

MNLO / Menlo Therapeutics Inc. 425 - Merger Prospectus - 8-K

425 1 d831422d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2019 (November 10, 2019) Menlo Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or ot

Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

EX-99.2 7 d831422dex992.htm EX-99.2 Exhibit 99.2 Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications • Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assets • Menlo’s serlopitant for pruritus associated with pr

Form of Foamix Voting Agreement, dated November 10, 2019, by and between Menlo Therapeutics Inc. and certain shareholders of Foamix Pharmaceuticals Ltd.

EX-10.2 Exhibit 10.2 FORM OF FOAMIX VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of [•], 2019, between Menlo Therapeutics Inc., a Delaware corporation (“Menlo”), and [•] (the “Stockholder”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below). RECITALS (

Form of CSR Agreement.

EX-10.3 Exhibit 10.3 CONTINGENT STOCK RIGHTS AGREEMENT by and between Menlo Therapeutics Inc. and [●] as Rights Agent Dated as of [●] TABLE OF CONTENTS Page Section 1. Holders of CSRs; Appointment of Rights Agent 2 Section 2. No Certificates 2 Section 3. Registration by the Rights Agent 2 Section 4. Rights of CSR Holder 2 Section 5. Non-transferability 3 Section 6. Transfer of CSRs 4 Section 7. Ex

Form of Menlo Voting Agreement, dated November 10, 2019, by and between Foamix Pharmaceuticals Ltd. and certain stockholders of Menlo Therapeutics Inc.

EX-10.1 Exhibit 10.1 FORM OF MENLO VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of [ ], 2019, between Foamix Pharmaceuticals Ltd., a company incorporated under the laws of the State of Israel and registered under No. 51-336881-1 with the Israeli Registrar of Companies (“Foamix”), and [•] (the “Stockholder”). Capitalized terms used but not otherwise defined

Warrant Certificate issued by Foamix Pharmaceuticals Ltd. for the benefit of Perceptive Credit Holdings II, LP

Exhibit 10.4 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING TH

U.S. Security Agreement among Foamix Pharmaceuticals Inc., Foamix Pharmaceuticals Ltd. and Perceptive Credit Holdings II, LP for the benefit of Perceptive Credit Holdings II, LP, OrbiMed Royalty & Credit Opportunities III, LP and the other lenders from time to time party to the Credit Agreement

Exhibit 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”), dated as of July 29, 2019, is made by and among Foamix Pharmaceuticals Inc., a Delaware corporation (the “Borrower”), Foamix Pharmaceuticals Ltd., an Israeli limited liability company (the “Parent Guarantor”), certain Subsidiaries of the Parent Guarantor party hereto or having acceded hereto pursuant to Section 22 (each a

Credit Agreement and Guaranty among Foamix Pharmaceuticals Inc., Foamix Pharmaceuticals Ltd., Perceptive Credit Holdings II, LP, OrbiMed Royalty & Credit Opportunities III, LP and the other lenders from time to time party thereto

Exhibit 10.1 CREDIT AGREEMENT AND GUARANTY dated as of July 29, 2019 by and among FOAMIX PHARMACEUTICALS INC., as the Borrower, FOAMIX PHARMACEUTICALS LTD., as the Parent Guarantor, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Subsidiary Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO as the Lenders, and PERCEPTIVE CREDIT HOLDINGS II, LP, as the Administrative Agent U.S.

September 30, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number: 001-36621 Foamix Ph

Warrant Certificate issued by Foamix Pharmaceuticals Ltd. for the benefit of OrbiMed Royalty & Credit Opportunities III, LP

Exhibit 10.3 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING TH

Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update

e Exhibit 99.1 Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update Conference Call and Webcast Scheduled for Monday, November 11th at 8:30am Eastern Time REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 11, 2019 - Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 zk1923620.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incor

Form of CSR Agreement

Exhibit 10.3 CONTINGENT STOCK RIGHTS AGREEMENT by and between Menlo Therapeutics Inc. and [•] as Rights Agent Dated as of [●] TABLE OF CONTENTS Page Section 1. Holders of CSRs; Appointment of Rights Agent 2 Section 2. No Certificates 2 Section 3. Registration by the Rights Agent 2 Section 4. Rights of CSR Holder 2 Section 5. Non-transferability 3 Section 6. Transfer of CSRs 3 Section 7. Exercisabi

Foamix Pharmaceuticals Inc. 520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807 Tel: +1 800 775-7936; e-mail: [email protected]; www.foamix.com

Exhibit 99.3 November 11, 2019 Dear Foamix Colleagues: This morning we announced that we have agreed to merge with Menlo Therapeutics in a transformative transaction that will combine two emerging pharmaceutical organizations into one dynamic dermatology company. Merging these two companies will create greater intrinsic value and support our future growth with 3 anticipated product launches throug

Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Exhibit 99.2 Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications • Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assets • Menlo’s serlopitant for pruritus associated with prurigo nodularis (“PN”) complements F

FORM OF FOAMIX VOTING AGREEMENT

Exhibit 10.2 SCHEDULE B-2 FORM OF FOAMIX VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of [•], 2019, between Menlo Therapeutics Inc., a Delaware corporation (“Menlo”), and [●] (the “Stockholder”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below). RECIT

Transaction Highlights Strategic combination expected to create a scaled player in the dermatological space with enhanced financial profile Merger creating a stronger dermatology focused companyEnhances the combined company’s late stage pipeline and

Exhibit 99.1 Investor Presentation | November 11, 2019 A Compelling Dermatology Combination Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Words such as “

Exhibit 2.1

Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG MENLO THERAPEUTICS INC. GIANTS MERGER SUBSIDIARY LTD. AND FOAMIX PHARMACEUTICALS LTD. DATED AS OF NOVEMBER 10, 2019 TABLE OF CONTENTS PAGE ARTICLE I THE MERGER Section 1.1 The Merger 3 Section 1.2 Closing; Effective Time 3 Section 1.3 Effect of the Merger 4 Section 1.4 Organizational Documents of Surviving Company 4 Section 1.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 (November 10, 2019) FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) Israel (State or other jurisdiction of incorporation) 001-36621 (

Form of Menlo Voting Agreement

Exhibit 10.1 SCHEDULE B-1 FORM OF MENLO VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of [ ], 2019, between Foamix Pharmaceuticals Ltd., a company incorporated under the laws of the State of Israel and registered under No. 51-336881-1 with the Israeli Registrar of Companies (“Foamix”), and [●] (the “Stockholder”). Capitalized terms used but not otherwise def

Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Exhibit 99.2 Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications • Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assets • Menlo’s serlopitant for pruritus associated with prurigo nodularis (“PN”) complements F

Foamix Pharmaceuticals Inc. 520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807 Tel: +1 800 775-7936; e-mail: [email protected]; www.foamix.com

Exhibit 99.3 November 11, 2019 Dear Foamix Colleagues: This morning we announced that we have agreed to merge with Menlo Therapeutics in a transformative transaction that will combine two emerging pharmaceutical organizations into one dynamic dermatology company. Merging these two companies will create greater intrinsic value and support our future growth with 3 anticipated product launches throug

FORM OF FOAMIX VOTING AGREEMENT

Exhibit 10.2 SCHEDULE B-2 FORM OF FOAMIX VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of [•], 2019, between Menlo Therapeutics Inc., a Delaware corporation (“Menlo”), and [●] (the “Stockholder”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below). RECIT

FOMX / Foamix Pharmaceuticals Ltd. 425 - Merger Prospectus - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 (November 10, 2019) FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) Israel (State or other jurisdiction of incorporation) 001-36621 (

Form of Menlo Voting Agreement

Exhibit 10.1 SCHEDULE B-1 FORM OF MENLO VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of [ ], 2019, between Foamix Pharmaceuticals Ltd., a company incorporated under the laws of the State of Israel and registered under No. 51-336881-1 with the Israeli Registrar of Companies (“Foamix”), and [●] (the “Stockholder”). Capitalized terms used but not otherwise def

Form of CSR Agreement

Exhibit 10.3 CONTINGENT STOCK RIGHTS AGREEMENT by and between Menlo Therapeutics Inc. and [•] as Rights Agent Dated as of [●] TABLE OF CONTENTS Page Section 1. Holders of CSRs; Appointment of Rights Agent 2 Section 2. No Certificates 2 Section 3. Registration by the Rights Agent 2 Section 4. Rights of CSR Holder 2 Section 5. Non-transferability 3 Section 6. Transfer of CSRs 3 Section 7. Exercisabi

Transaction Highlights Strategic combination expected to create a scaled player in the dermatological space with enhanced financial profile Merger creating a stronger dermatology focused companyEnhances the combined company’s late stage pipeline and

Exhibit 99.1 Investor Presentation | November 11, 2019 A Compelling Dermatology Combination Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Words such as “

Exhibit 2.1*

Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG MENLO THERAPEUTICS INC. GIANTS MERGER SUBSIDIARY LTD. AND FOAMIX PHARMACEUTICALS LTD. DATED AS OF NOVEMBER 10, 2019 TABLE OF CONTENTS PAGE ARTICLE I THE MERGER Section 1.1 The Merger 3 Section 1.2 Closing; Effective Time 3 Section 1.3 Effect of the Merger 4 Section 1.4 Organizational Documents of Surviving Company 4 Section 1.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission Fil

Foamix Announces Issuance of New U.S. Patent for Compositions Combining a Retinoid and a Tetracycline Antibiotic

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Announces Issuance of New U.S. Patent for Compositions Combining a Retinoid and a Tetracycline Antibiotic REHOVOT, Israel, and BRIDGEWATER, NJ, November 7, 2019 – Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office has issued U

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission Fil

Foamix Enters Into Manufacturing and Supply Agreement For AMZEEQ™ and FMX103 Triggers availability of non-dilutive capital under existing credit agreement with Perceptive and OrbiMed

Exhibit 99.1 Foamix Enters Into Manufacturing and Supply Agreement For AMZEEQ™ and FMX103 Triggers availability of non-dilutive capital under existing credit agreement with Perceptive and OrbiMed REHOVOT, Israel and BRIDGEWATER, N.J., October 23, 2019 – Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that it has entered in

Foamix Receives FDA Approval of AMZEEQTM Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Receives FDA Approval of AMZEEQTM Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption REHOVOT, Israel and BRIDGEWATER, N.J., October 18th, 2019 - Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foam

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission Fil

Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea PDUFA Target Action Date of June 2nd, 2020

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea PDUFA Target Action Date of June 2nd, 2020 Rehovot, Israel, and Bridgewater, NJ – October 17th, 2019 – Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company

Financial Statements and Exhibits, Other Events

8-K 1 zk1923538.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorp

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission F

Foamix Announces Enrollment of First Patient in Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam

Exhibit 99.1 Foamix Announces Enrollment of First Patient in Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam Rehovot, Israel, and Bridgewater, NJ – September 19th, 2019 – Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), today announced that the first patient has been enrolled in its Phase 2 clinical trial to evaluate the efficacy and safety of its topical combin

Foamix Announces Issuance of New U.S. Patent Covering A Method of Treating Acne that Expires in 2037

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Announces Issuance of New U.S. Patent Covering A Method of Treating Acne that Expires in 2037 Rehovot, Israel, and Bridgewater, NJ – September 4th, 2019 (GLOBE NEWSWIRE) – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing propr

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission Fi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 19, 2019 Date of Report (Date of earliest event reported) Foamix Pharmaceuticals Ltd. (Exact name of registrant as specified in its charter) Israel 001-36621 Not applicable (State or other jurisdiction of incorporation) (Commi

Foamix Pharmaceuticals Ltd. Ordinary Shares (par value NIS 0.16 per share) Controlled Equity OfferingSM Sales Agreement

EX-1.1 2 exhibit1-1.htm EXHIBIT 1.1 Exhibit 1.1 Foamix Pharmaceuticals Ltd. Ordinary Shares (par value NIS 0.16 per share) Controlled Equity OfferingSM Sales Agreement August 19, 2019 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Foamix Pharmaceuticals Ltd., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “A

Up to $30,000,000 Ordinary Shares

424B5 1 zk1923415.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-224084 PROSPECTUS SUPPLEMENT (To Prospectus dated April 12, 2018) Up to $30,000,000 Ordinary Shares On August 19, 2019, we entered into a Controlled Equity OfferingSM Sales Agreement, or Sales Agreement, with Cantor Fitzgerald & Co., or Cantor, as sales agent, relating to our ordinary shares, par value 0.16 New Israe

JOINT FILING AGREEMENT

EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Ordinary Shares, par value NIS 0.16, of Foamix Pharmaceuticals Ltd., a company organized under the laws of th

FOMX / Foamix Pharmaceuticals Ltd. / Delaware Street Capital Master Fund, L.P. - SC 13G Passive Investment

SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Foamix Pharmaceuticals Ltd.

Foamix Reports Second Quarter 2019 Financial Results and Provides Corporate Update Conference Call Scheduled for Thursday, August 8th at 8:30am Eastern Time

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Reports Second Quarter 2019 Financial Results and Provides Corporate Update Conference Call Scheduled for Thursday, August 8th at 8:30am Eastern Time Rehovot, Israel, and Bridgewater, NJ, August 7, 2019 – Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on dev

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File

June 30, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number: 001-36621 Foamix Pharmac

FOMX / Foamix Pharmaceuticals Ltd. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d786754dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Foamix Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.16 per share (Title of Class of Securities) M46135105 (CUSIP Number) July 29, 2019 (Date of Event Which Requires Filing of this Statement

Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea Rehovot, Israel, and Bridgewater, NJ – August 5th , 2019 – Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies t

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Exact name of registrant as specified in its charter) July 29, 2019 Date of Report (Date of earliest event reported) Foamix Pharmaceuticals Ltd. Israel 001-36621 Not applicable (State or other jurisdiction of incorporation) (Commiss

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (as may be amended, modified, or supplemented from time to time, this “Agreement”) is made and entered into as of July 29, 2019, by and between Foamix Pharmaceuticals Ltd., a company organized under the laws of the State of Israel (the “Company”) and Perceptive Life Sciences Master Fund, Ltd., a Cayman Islands corporatio

Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMed

EX-99.1 4 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMed • Foamix secures up to $50 million in non-dilutive funding • Company secures $14 million via a registered direct offering of equity Rehovot, Israel, and Bridgewater, NJ – July 30, 2019 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical s

6,542,057 Shares Foamix Pharmaceuticals Ltd. Ordinary Shares

424B5 1 zk1923327.htm 424B5 Filed Pursuant to Rule 424(B)(5) Registration Statement No. 333-224084 PROSPECTUS SUPPLEMENT (To Prospectus dated April 12, 2018) 6,542,057 Shares Foamix Pharmaceuticals Ltd. Ordinary Shares We are offering 6,542,057 of our ordinary shares to an institutional investor pursuant to this prospectus supplement and the accompanying prospectus and a securities purchase agreem

Foamix Reports First Quarter 2019 Financial Results and Provides Corporate Update FDA Accepts NDA for FMX101, Sets October 20, 2019 as PDUFA Action Date Conference Call Scheduled for Wednesday May 8th at 8:30am Eastern Time

Exhibit 99.1 Foamix Reports First Quarter 2019 Financial Results and Provides Corporate Update FDA Accepts NDA for FMX101, Sets October 20, 2019 as PDUFA Action Date Conference Call Scheduled for Wednesday May 8th at 8:30am Eastern Time Rehovot, Israel, and Bridgewater, NJ, May 7, 2019 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specia

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 zk1923047.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporati

Amendment to offer letter agreement between Foamix Pharmaceuticals Inc. and Mutya Harsch

EX-10.2 4 exhibit10-2.htm EXHIBIT 10.2 Exhibit 10.2 AMENDMENT TO EMPLOYMENT OFFER LETTER FOR CHANGE OF CONTROL This Letter Agreement is made on May 6, 2019 between Mutya Harsch (“Executive”), Foamix Pharmaceuticals Ltd. (“Foamix”) and Foamix Pharmaceuticals Inc., a wholly-owned subsidiary of Foamix (“Foamix Pharmaceuticals Inc.”). Reference is made to the Offer Employment Letter (the “Offer Letter

Form of U.S. Share Option Grant Notice and Option Agreement under the Foamix Pharmaceuticals Ltd. 2019 Equity Incentive Plan

Exhibit 10.4 Foamix Pharmaceuticals Ltd. Share Option Grant Notice (2019 Equity Incentive Plan) Foamix Pharmaceuticals Ltd. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of Shares set forth below. This option is subject to all of the terms and conditions as set forth in this Share Option Grant Notice, in the

Form of U.S. Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under the Foamix Pharmaceuticals Ltd. 2019 Equity Incentive Plan

Exhibit 10.5 Foamix Pharmaceuticals Ltd. Restricted Share Unit Grant Notice (2019 Equity Incentive Plan) Foamix Pharmaceuticals Ltd. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Share Unit Award for the number of Shares (“Restricted Share Units”) set forth below (the “Award”). The Award is subject to all of the terms and condit

Amended and Restated Articles of Association of Foamix Pharmaceuticals Ltd.

Exhibit 3.1 ARTICLES OF ASSOCIATION OF FOAMIX PHARMACEUTICLS LTD. A COMPANY LIMITED BY SHARES UNDER THE COMPANIES LAW, 5759 – 1999 1. INTERPRETATION 1.1. In these Articles, unless the context requires otherwise, the following capitalized terms shall have the meanings set opposite them: “Alternate Nominee” has the meaning set out in Article 17.2; “Articles” means these Articles of Association, as m

Foamix Pharmaceuticals Ltd. 2019 Equity Incentive Plan

EX-10.3 5 exhibit10-3.htm EXHIBIT 10.3 Exhibit 10.3 AMENDMENT TO EMPLOYMENT AGREEMENT FOR CHANGE OF CONTROL This Letter Agreement is made on May 6, 2019 between ILAN HADAR (“Employee”) and Foamix Pharmaceuticals Ltd. (“Foamix”). Reference is made to the employment agreement (the “Employment Agreement”) dated as of September 13, 2017, between Executive and Foamix. In order to attract and retain the

March 31, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number: 001-36621 Foamix Pharma

Amendment to offer letter agreement between Foamix Pharmaceuticals Inc. and Mutya Harsch

Exhibit 10.1 FIRST AMENDMENT TO LEASE (the “First Amendment”) dated as of March 13, 2019, between S/K 520 ASSOCIATES (the “Landlord”), whose mailing address is P.O. Box 6872, 520 US Highway 22, Bridgewater, NJ 08807, and FOAMIX PHARMACEUTICALS INC., (the “Tenant”), having an office at 520 US Highway 22, Bridgewater, NJ 08807. W I T N E S S E T H : WHEREAS, Tenant entered into a lease with Landlord

Foamix Pharmaceuticals Ltd. 2019 Equity Incentive Plan.

EX-99.1 4 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Pharmaceuticals Ltd. 2019 Equity Incentive Plan Adopted by the Board of Directors: February 28, 2019 Approved by the Shareholders: April 10, 2019 1. General. (a) Successor to and Continuation of 2015 Plan. The Plan is intended as the successor to and continuation of the Company’s 2015 Israeli Share Incentive Plan, as amended from time to t

Forms of U.S. Share Option Agreement, Share Option Grant Notice, Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under the Foamix Pharmaceuticals Ltd. 2019 Equity Incentive Plan.

EX-99.2 5 exhibit99-2.htm EXHIBIT 99.2 Exhibit 99.2 Foamix Pharmaceuticals Ltd. Share Option Grant Notice (2019 Equity Incentive Plan) Foamix Pharmaceuticals Ltd. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of Shares set forth below. This option is subject to all of the terms and conditions as set forth in

Forms of Israeli Share Option Agreement, Share Option Grant Notice, Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under the Foamix Pharmaceuticals Ltd. 2019 Equity Incentive Plan.

EX-99.3 6 exhibit99-3.htm EXHIBIT 99.3 Exhibit 99.3 For Israeli employees and service providers Foamix Pharmaceuticals Ltd. Share Option Grant Notice (2019 Equity Incentive Plan) Foamix Pharmaceuticals Ltd. (the “Company”), pursuant to its 2019 Equity Incentive Plan including its Sub-Plan for Israeli Participants (jointly the “Plan”), hereby grants to Optionholder an option to purchase the number

FOMX / Foamix Pharmaceuticals Ltd. S-8

S-8 1 zk1922954.htm S-8 As filed with the Securities and Exchange Commission on April 18, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel Not Applicable (State or other jurisdiction of in

Foamix Pharmaceuticals Ltd. 2019 Employee Share Purchase Plan

EXHIBIT 99.4 Foamix Pharmaceuticals Ltd. 2019 Employee Share Purchase Plan Adopted by the Board of Directors: February 28, 2019 Approved by the Shareholders: April 10, 2019 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase Shares. The Plan permits the Company to grant a s

2019 Employee Share Purchase Plan

EX-10.2 3 exhibit10-2.htm EXHIBIT 10.2 Exhibit 10.2 Foamix Pharmaceuticals Ltd. 2019 Employee Share Purchase Plan Adopted by the Board of Directors: February 28, 2019 Approved by the Shareholders: April 10, 2019 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase Shares. Th

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (date of earliest event reported): April 10, 2019 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File Num

2019 Equity Incentive Plan

EX-10.1 2 exhibit10-1.htm EXHIBIT 10.1 Exhibit 10.1 Foamix Pharmaceuticals Ltd. 2019 Equity Incentive Plan Adopted by the Board of Directors: February 28, 2019 Approved by the Shareholders: April 10, 2019 1. General. (a) Successor to and Continuation of 2015 Plan. The Plan is intended as the successor to and continuation of the Company’s 2015 Israeli Share Incentive Plan, as amended from time to t

2019 Employee Share Purchase Plan (incorporated by reference to Appendix B to Foamix Pharmaceuticals Ltd.’s Proxy Statement on Form DEF 14A filed on March 11, 2019).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of

FOMX / Foamix Pharmaceuticals Ltd. PRE 14A

PRER14A 1 zk1922787.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Stat

FOMX / Foamix Pharmaceuticals Ltd.

Divakar Gupta +1 212 479 6474 [email protected] March 8, 2019 Via EDGAR and Electronic Mail Ms. Dorrie Yale United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Foamix Pharmaceuticals Ltd. Preliminary Proxy Statement on Schedule 14A Filed March 1, 2019 File No. 001-36621 Ladies and Gentlemen: On behalf of Foamix Pharmaceutic

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File N

Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne PDUFA Target Action Date of October 20th, 2019

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne PDUFA Target Action Date of October 20th, 2019 Rehovot, Israel, and Bridgewater, NJ – March 7th, 2019 – Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing

FOMX / Foamix Pharmaceuticals Ltd. PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission Fi

Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update Conference Call Scheduled for Friday, March 1 at 8:30am Eastern Time

Exhibit 99.1 Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update Conference Call Scheduled for Friday, March 1 at 8:30am Eastern Time Rehovot, Israel, and Bridgewater, NJ, February 28, 2019 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing

EMPLOYMENT AGREEMENT

Exhibit 10.6 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”'), is made and entered into as of November 27, 2017, by and between Foamix Pharmaceuticals Inc., a company registered in the state of New Jersey (the “Company”) and David Domzalski (the “Executive”'). Where the context permits, references to “the Company” shall include the Company and any successor thereto. WHEREAS, the

Foamix Pharmaceuticals Ltd. Lease Agreement – Premises in Rehovot

Exhibit 10.3 Foamix Pharmaceuticals Ltd. Lease Agreement – Premises in Rehovot On May 7, 2008 Foamix Pharmaceuticals Ltd. (the “Company”) executed a lease agreement with Gav Yam Real Estate Ltd. (the “Lessor” and the “Original Agreement”). Leased property: 1,069 square meters (approximately 11,507 square feet) in A2 building, first floor, located in the Science Park in Rehovot. Original Agreement

Amended and Restated Articles of Association of the Company

Exhibit 3.1 ARTICLES OF ASSOCIATION OF FOAMIX PHARMACEUTICLS LTD. A COMPANY LIMITED BY SHARES UNDER THE COMPANIES LAW, 5759 – 1999 1. INTERPRETATION 1.1. In these Articles, unless the context requires otherwise, the following capitalized terms shall have the meanings set opposite them: “Alternate Nominee” has the meaning set out in Article 17.2; “Articles” means these Articles of Association, as m

LEASE AND LEASE AGREEMENT S/K 520 ASSOCIATES The Landlord FOAMIX PHARMACEUTICALS INC. The Tenant For Leased Premises In 520 Route 22, Bridgewater, New Jersey October 25th, 2017

EX-10.9 8 exhibit10-9.htm EXHIBIT 10.9 Exhibit 10.9 LEASE AND LEASE AGREEMENT Between S/K 520 ASSOCIATES The Landlord And FOAMIX PHARMACEUTICALS INC. The Tenant For Leased Premises In 520 Route 22, Bridgewater, New Jersey October 25th, 2017 Prepared by: Gary O. Turndorf 520 Route 22 P.O. Box 6872 Bridgewater, NJ 08807 (908) 725-8100 TABLE OF CONTENTS Page 1. DEFINITIONS. 1 2. LEASE OF THE LEASED P

Personal Employment Agreement (A notice to the employee about terms of employment) entered into and executed in Rehovot as of September 13, 2017

Exhibit 10.7 Personal Employment Agreement (A notice to the employee about terms of employment) entered into and executed in Rehovot as of September 13, 2017 BY AND BETWEEN: Foamix Pharmaceuticals Ltd. a company organized under the laws of Israel (company number 51-336881-1), with business address at 2 Holzman St., Rehovot, 7670402 Israel (the "Company") On the one hand AND BETWEEN: Ilan Hadar ID

List of Subsidiaries of Foamix Pharmaceuticals Ltd.

Exhibit 21.1 Foamix Pharmaceuticals Ltd. The following is a list of subsidiaries of Foamix Pharmaceutical Ltd. as of December 31, 2018: SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Foamix Pharmaceutical Inc. Delaware

Foamix Pharmaceuticals Inc. 520 U.S. Highway 22, Suite 305, Bridgewater, New Jersey 08807 Tel: +1 800 775-7936; e-mail: [email protected]; www.Foamix.co.il

Exhibit 10.8 November 1st, 2017 Mutya Harsch Dear Mutya: Foamix Pharmaceuticals Inc., a Delaware-based company (the “Company”), is pleased to propose the following offer of employment for the position of: General Counsel & Senior Vice President Legal Affairs Your employment will commence on January 2nd, 2018, subject to your acceptance of this offer letter. This offer is contingent upon successful

Foamix Pharmaceuticals Ltd. Amended Compensation Policy for Officers and Directors

Exhibit 10.5 Compensation Policy Foamix Pharmaceuticals Ltd. and subsidiaries ("Foamix" or the "Company") Compensation Policy for Officers and Directors Table of Contents 1. Background 2 2. Compensation Objectives 3 3. Compensation policy 4 3.1. Officers’ Compensation Package Components 4 3.2. Base Salary 4 3.3. Benefits and Perquisites 6 3.4. Cash Bonus 7 3.5. Equity based Compensation 10 3.6. Re

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36621 Foamix Pharmace

FOMX / Foamix Pharmaceuticals Ltd. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Foamix Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.16 per share (Title of Class of Securities) M46135105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

FOMX / Foamix Pharmaceuticals Ltd. / GREAT POINT PARTNERS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Foamix Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.16 per share (Title of Class of Securities) M46135105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de

FOMX / Foamix Pharmaceuticals Ltd. / Baker Brothers Advisors LP - SC 13G/A Passive Investment

SC 13G/A 1 tv511583sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 2)* Foamix Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, par value NIS $0.16 per share (Title of Class of Securities) M46135105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the

FOMX / Foamix Pharmaceuticals Ltd. / Orbimed Capital Llc Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Foamix Announces Appointment of Sharon Barbari to Board of Directors

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Announces Appointment of Sharon Barbari to Board of Directors Rehovot, Israel, and Bridgewater, NJ – January 23, 2019 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission Fil

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2019 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File

Foamix Announces Appointment of Anthony Bruno to Board of Directors

Exhibit 99.1 Foamix Announces Appointment of Anthony Bruno to Board of Directors Rehovot, Israel, and Bridgewater, NJ – November 19 2018 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Anthony Bruno to its Boar

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2018 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission Fi

Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to- Severe Papulopustular Rosacea FMX103 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co

EX-99.3 4 exhibit99-3.htm EXHIBIT 99.3 Exhibit 99.3 Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to- Severe Papulopustular Rosacea FMX103 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints Conference Call and Webcast Today at 8:30 a.m. ET Rehovot, Israel, and

Nasdaq: FOMXNovember 2018 FMX103FX2016-11 & FX2016-12Top Line Results Topical Minocycline Foam 1.5%For Moderate-to-Severe Papulopustular Rosacea 3 FMX103 Phase 3 Program Design Studies FX2016-11, FX2016-12 & FX2016-13 4 12-week, randomized, double-bl

EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 Exhibit 99.2 Nasdaq: FOMXNovember 2018 Forward-Looking Statements and Where to Find More Information 2 To the extent that statements contained in this presentation are not descriptions of historical facts regarding Foamix, they are forward-looking statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to kn

Foamix Reports Third Quarter 2018 Financial Results and Provides Corporate Update Conference Call and Webcast Thursday, November 8, @ 8.30 am Eastern Time

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Reports Third Quarter 2018 Financial Results and Provides Corporate Update Conference Call and Webcast Thursday, November 8, @ 8.30 am Eastern Time Rehovot, Israel, November 7, 2018 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercia

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2018 FOAMIX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission

Amended and Restated Articles of Association of Foamix Pharmaceuticals Ltd.

Exhibit 3.1 ARTICLES OF ASSOCIATION OF FOAMIX PHARMACEUTICLS LTD. A COMPANY LIMITED BY SHARES UNDER THE COMPANIES LAW, 5759 – 1999 1. INTERPRETATION 1.1. In these Articles, unless the context requires otherwise, the following capitalized terms shall have the meanings set opposite them: “Alternate Nominee” has the meaning set out in Article 17.2; “Articles” means these Articles of Association, as m

FOMX / Foamix Pharmaceuticals Ltd. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number: 001-001-36621 Foamix Pharmaceuticals Ltd.

FOMX / Foamix Pharmaceuticals Ltd. / GREAT POINT PARTNERS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Foamix Pharmaceuticals Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) M46135105 (CUSIP Number) September 30, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2018 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File Nu

Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne

Exhibit 99.1 Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne · Statistically significant improvement demonstrated in reduction of non-inflammatory lesions · Dermal tolerability scores consistent with previous Phase 3 studies · Re-analysis including patients from discontinued inves

FOMX / Foamix Pharmaceuticals Ltd. / PERCEPTIVE ADVISORS LLC - SCHEDULE 13G Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Foamix Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.16 per share (Title of Class of Securities) M46135105 (CUSIP Number) September 14, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriat

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2018 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) Israel (State or other jurisdiction of incorporation) 001-36621 (Commission File Num

Exhibit 1.1

EX-1.1 2 exhibit1-1.htm EXHIBIT 1.1 Exhibit 1.1 Execution Version 11,670,000 FOAMIX PHARMACEUTICALS LTD. Ordinary Shares UNDERWRITING AGREEMENT September 13, 2018 Merrill Lynch, Pierce, Fenner & Smith Incorporated Cowen and Company, LLC Barclays Capital Inc. As Representatives of the several Underwriters named in Schedule I attached hereto, c/o Merrill Lynch Pierce, Fenner & Smith Incorporated One

11,670,000 Shares Foamix Pharmaceuticals Ltd. Ordinary Shares

Filed pursuant to Rule 424(b)(2) Registration Statement No. 333-224084 P R O S P E C T U S S U P P L E M E N T (To Prospectus dated April 12, 2018) 11,670,000 Shares   Foamix Pharmaceuticals Ltd. Ordinary Shares We are offering 11,670,000 of our ordinary shares. Our ordinary shares are listed on the Nasdaq Global Market under the symbol “FOMX.” On September 11, 2018, the last reported sales price

Subject to Completion Preliminary Prospectus Supplement dated September 12, 2018

Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-224084 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2018 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File

Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne FMX101 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both

EX-99.2 3 exihibit99-2.htm EXHIBIT 99.2 Exhibit 99.2 Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne FMX101 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints Conference Call and Webcast Tomorrow at 8:00 a.m. EDT Rehovot, Isr

Nasdaq: FOMXSeptember 2018 FMX101FX2017-22 Top Line Results Topical Minocycline Foam 4%For Moderate-to-Severe Acne 3 FMX101 3rd Phase 3 Study DesignStudy FX2017-22 (“Study 22”) 4 12-week, randomized, multi-center, double-blind, vehicle controlled, in

Exhibit 99.1 Nasdaq: FOMXSeptember 2018 Forward-Looking Statements and Where to Find More Information 2 To the extent that statements contained in this presentation are not descriptions of historical facts regarding Foamix, they are forward-looking statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties,

FOMX / Foamix Pharmaceuticals Ltd. 10-Q (Quarterly Report)

10-Q 1 zk1821984.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number:

Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103 Top-line results expected early Q4 2018

Exhibit 99.1 Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103 Top-line results expected early Q4 2018 Rehovot, Israel, and Bridgewater, NJ – June 27, 2018 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatolo

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2018 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File Numb

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (date of earliest event reported): May 14, 2018 (May 8, 2018) FOAMIX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commiss

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2018 (May 8, 2018) FOAMIX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commissi

Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update Conference Call and Webcast on Wednesday, May 9 at 8:30am Eastern Time

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update Conference Call and Webcast on Wednesday, May 9 at 8:30am Eastern Time Rehovot, Israel, May 8, 2018 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing

FOMX / Foamix Pharmaceuticals Ltd. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number: 001-33299 Foamix Pharmaceuticals Ltd.

Foamix Announces Dosing of Last Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101 Top-line Results Expected in the Third Quarter of 2018

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Announces Dosing of Last Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101 Top-line Results Expected in the Third Quarter of 2018 Rehovot, Israel, and Bridgewater, NJ – May 7th, 2018 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing propri

FOMX / Foamix Pharmaceuticals Ltd. 6-K (Current Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2018 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File Number

2,940,000 Shares Foamix Pharmaceuticals Ltd. Ordinary Shares

Filed Pursuant to Rule 424(B)(5) Registration Statement No. 333-224084 PROSPECTUS SUPPLEMENT (To Prospectus dated April 12, 2018) 2,940,000 Shares   Foamix Pharmaceuticals Ltd. Ordinary Shares We are offering 2,940,000 of our ordinary shares to an institutional investor pursuant to this prospectus supplement and the accompanying prospectus and a securities purchase agreement with such investor. Th

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 zk1821491.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2018 (April 13, 2018) FOAMIX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Israel 001-36621 N/A (State or other jurisdicti

SECURITIES PURCHASE AGREEMENT

EX-10.1 3 exhibit10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (as may be amended, modified, or supplemented from time to time, this “Agreement”) is made and entered into as of April 13, 2018, by and between Foamix Pharmaceuticals Ltd., a company organized under the laws of the State of Israel (the “Company”) and OrbiMed Partners Master Fund Li

FOMX / Foamix Pharmaceuticals Ltd. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of

FOMX / Foamix Pharmaceuticals Ltd. CORRESP

Foamix Pharmaceuticals Ltd. 2 Holzman Street, Weizmann Science Park Rehovot 7670402, Israel April 10, 2018 BY EDGAR Suzanne Hayes Assistant Director Securities and Exchange Commission Office of Healthcare and Insurance 100 F Street, N.E. Washington, DC 20549 Re: Foamix Pharmaceuticals Ltd. Registration Statement on Form S-3 (File No. 333-224084) Dear Ms. Hayes: Pursuant to Rule 461 under the Secur

FOMX / Foamix Pharmaceuticals Ltd. S-3

As filed with the Securities and Exchange Commission on April 2, 2018 Registration No.

Other Events, Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2018 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File Num

Foamix Pharmaceuticals Ltd. 2019 Employee Share Purchase Plan

Exhibit 10.7 Termination Agreement This Termination Agreement ("Agreement") is entered into as of July 1, 2017 (the "Effective Date") by and between Foamix Pharmaceuticals Ltd., a company organized under the laws of the State of Israel, whose principal place of business is located at 2 Chaim Holzman St., Rehovot, Israel, (the "Company") and Mr. Meir Eini (“Executive”). WHEREAS The Executive has be

Forms of Israeli Share Option Agreement, Share Option Grant Notice, Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under the Foamix Pharmaceuticals Ltd. 2019 Equity Incentive Plan.

Exhibit 10.6 Termination Agreement This Termination Agreement ("Agreement") is entered into as of July 1, 2017 (the "Effective Date") by and between Foamix Pharmaceuticals Ltd., a company organized under the laws of the State of Israel, whose principal place of business is located at 2 Chaim Holzman St., Rehovot, Israel, (the "Company") and Dr. Dov Tamarkin (“Executive”). WHEREAS The Executive has

LEASE AND LEASE AGREEMENT S/K 520 ASSOCIATES The Landlord FOAMIX PHARMACEUTICALS INC. The Tenant For Leased Premises In 520 Route 22, Bridgewater, New Jersey October 25th, 2017

Exhibit 10.8 LEASE AND LEASE AGREEMENT Between S/K 520 ASSOCIATES The Landlord And FOAMIX PHARMACEUTICALS INC. The Tenant For Leased Premises In 520 Route 22, Bridgewater, New Jersey October 25th, 2017 Prepared by: Gary O. Turndorf 520 Route 22 P.O. Box 6872 Bridgewater, NJ 08807 (908) 725-8100 TABLE OF CONTENTS Page 1. DEFINITIONS. 1 2. LEASE OF THE LEASED PREMISES. 1 3. RENT. 1 4. TERM. 2 5. PRE

FOMX / Foamix Pharmaceuticals Ltd. 10-K/A (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-332

LEASE AND LEASE AGREEMENT S/K 520 ASSOCIATES The Landlord FOAMIX PHARMACEUTICALS INC. The Tenant For Leased Premises In 520 Route 22, Bridgewater, New Jersey October 25th, 2017

Exhibit 10.8 LEASE AND LEASE AGREEMENT Between S/K 520 ASSOCIATES The Landlord And FOAMIX PHARMACEUTICALS INC. The Tenant For Leased Premises In 520 Route 22, Bridgewater, New Jersey October 25th, 2017 Prepared by: Gary O. Turndorf 520 Route 22 P.O. Box 6872 Bridgewater, NJ 08807 (908) 725-8100 TABLE OF CONTENTS Page 1. DEFINITIONS. 1 2. LEASE OF THE LEASED PREMISES. 1 3. RENT. 1 4. TERM. 2 5. PRE

FOMX / Foamix Pharmaceuticals Ltd. 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33299 Foamix Pharmace

Termination Agreement

EX-10.7 3 exhibit10-7.htm EXHIBIT 10.7 Exhibit 10.7 Termination Agreement This Termination Agreement ("Agreement") is entered into as of July 1, 2017 (the "Effective Date") by and between Foamix Pharmaceuticals Ltd., a company organized under the laws of the State of Israel, whose principal place of business is located at 2 Chaim Holzman St., Rehovot, Israel, (the "Company") and Mr. Meir Eini (“Ex

Termination Agreement

Exhibit 10.6 Termination Agreement This Termination Agreement (" Agreement") is entered into as of July 1, 2017 (the " Effective Date") by and between Foamix Pharmaceuticals Ltd., a company organized under the laws of the State of Israel, whose principal place of business is located at 2 Chaim Holzman St., Rehovot, Israel, (the " Company") and Dr. Dov Tamarkin (? Executive?). WHEREAS The Executive

FOMX / Foamix Pharmaceuticals Ltd. / GREAT POINT PARTNERS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Foamix Pharmaceuticals Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) M46135105 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic

FOMX / Foamix Pharmaceuticals Ltd. / Eini Meir - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Foamix Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, NIS 0.16 par value per share (Title of Class of Securities) M46135105 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design

FOMX / Foamix Pharmaceuticals Ltd. / Tamarkin Dov - SC 13G Passive Investment

SC 13G 1 zk1821193.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Foamix Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, NIS 0.16 par value per share (Title of Class of Securities) M46135105 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2018 (January 24, 2018) FOAMIX PHARMACEUTICALS LTD. (Translation of registrant?s name into English) Israel 001-36621 N/A (State or other jurisdiction of incorporation)

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

FOMX / Foamix Pharmaceuticals Ltd. EXHIBIT 24

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Exhibit 24 POWER OF ATTORNEY For Executing Forms 3, 4 and 5 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd.

Nasdaq: FOMXJanuary 2018 Foamix Value Proposition 3 Late-stage Products with Potential to Differentiate vs. Market LeadersGlobal, Unencumbered Rights to Lead Programs Innovative Platform Allows for Consistent, Organic Innovation Extensive IP portfoli

Exhibit 99.1 Nasdaq: FOMXJanuary 2018 Disclaimer To the extent that statements contained in this presentation are not descriptions of historical facts regarding Foamix, they are forward-looking statements reflecting management?s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry?s

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2018 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant?s name into English) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File Nu

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2018 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant?s name into English) Israel 001-36621 N/A (State or other jurisdiction of incorporation) (Commission File Nu

Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year Long Term Data on FMX-101 in Moderate-to-Severe Acne to be Presented at Winter Clinical Dermatology Conf

Exhibit 99.1 Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year Long Term Data on FMX-101 in Moderate-to-Severe Acne to be Presented at Winter Clinical Dermatology Conference (January 12 th-17 th) Rehovot, Israel, and Bridgewater, NJ – January 4, 2018 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foami

Foamix Names Mr. David Domzalski as a Member of the Board of Foamix Pharmaceuticals

Exhibit 99.1 Foamix Names Mr. David Domzalski as a Member of the Board of Foamix Pharmaceuticals Rehovot, Israel, and Bridgewater, NJ ? January 3, 2018 ? Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (?Foamix?), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2018 (January 1, 2018) FOAMIX PHARMACEUTICALS LTD. (Translation of registrant?s name into English) Israel 001-36621 Not Applicable (State or other jurisdiction of incor

Amended and Restated Articles of Association of the Company

Exhibit 4.1 ARTICLES OF ASSOCIATION OF FOAMIX PHARMACEUTICLS LTD. A COMPANY LIMITED BY SHARES UNDER THE COMPANIES LAW, 5759 ? 1999 1. INTERPRETATION 1.1. In these Articles, unless the context requires otherwise, the following capitalized terms shall have the meanings set opposite them: ? Alternate Nominee? has the meaning set out in Article 17.2; ? Articles? means these Articles of Association, as

FOMX / Foamix Pharmaceuticals Ltd. S-8

As filed with the Securities and Exchange Commission on December 19, 2017 Registration No.

FOMX / Foamix Pharmaceuticals Ltd. 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission file number: 001-36621 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) 2 Holzman Street, Weizmann Science Park Rehovot, Israel (Address of p

Foamix Reports Third Quarter 2017 Financial Results and Provides Business Update Conference Call and Webcast on Wednesday, November 15, 2017 at 8:30am Eastern / 5:30am Pacific

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 News Release November 14, 2017 Foamix Reports Third Quarter 2017 Financial Results and Provides Business Update Conference Call and Webcast on Wednesday, November 15, 2017 at 8:30am Eastern / 5:30am Pacific Rehovot, Israel, November 14, 2017 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage

FOMX / Foamix Pharmaceuticals Ltd. 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission file number: 001-36621 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) 2 Holzman Street, Weizmann Science Park Rehovot, Israel (Address of p

Foamix Pharmaceuticals 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission file number: 001-36621 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) 2 Holzman Street, Weizmann Science Park Rehovot, Israel (Address of pr

FOAMIX PHARMACEUTICALS LTD. 2 Holzman Street, Weizmann Science Park Rehovot, Israel October 23, 2017 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 27, 2017

Exhibit 99.1 ? FOAMIX PHARMACEUTICALS LTD. 2 Holzman Street, Weizmann Science Park Rehovot, Israel October 23, 2017 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 27, 2017 Dear Shareholders: We cordially invite you to attend an extraordinary general meeting of shareholders, or the Meeting, of Foamix Pharmaceuticals Ltd., or the Company, to be held at 3:00 p.m. (Isra

Foamix Pharmaceuticals Ltd.

Exhibit 99.2 Foamix Pharmaceuticals Ltd. PROXY FOR EXTRAORDINARY MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 27, 2017 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints each of Stanley Hirsch and Ilan Hadar as the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote, o

Foamix Pharmaceuticals 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission file number: 001-36621 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) 2 Holzman Street, Weizmann Science Park Rehovot, Israel (Address of

Foamix Reports Second Quarter 2017 Financial Results and Provides Business Update Conference Call and Webcast on Wednesday, August 9, 2017 at 8:30am Eastern / 5:30am Pacific

Exhibit 99.1 News Release August 8, 2017 Foamix Reports Second Quarter 2017 Financial Results and Provides Business Update Conference Call and Webcast on Wednesday, August 9, 2017 at 8:30am Eastern / 5:30am Pacific Rehovot, Israel, August 8, 2017 ? Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (?Foamix Pharmaceuticals? or the ?Company?), a clinical stage specialty pharmaceutical company focused on de

Foamix Pharmaceuticals 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission file number: 001-36621 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) 2 Holzman Street, Weizmann Science Park Rehovot, Israel (Address of pri

FOAMIX PHARMACEUTICALS LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2017 FOAMIX PHARMACEUTICALS LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2017 TABLE OF CONTENTS

Exhibit 99.2 FOAMIX PHARMACEUTICALS LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2017 FOAMIX PHARMACEUTICALS LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2017 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Balance sheets 2-3 Statements of operations 4 Statements of comprehensive loss 5 Statements of changes in sharehold

Foamix Pharmaceuticals 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2017 Commission file number: 001-36621 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) 2 Holzman Street, Weizmann Science Park Rehovot, Israel (Address of princ

Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer

Exhibit 99.1 Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer Rehovot, Israel, and Bridgewater, NJ ? June 29, 2017 ? Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (?Foamix?), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that its Board of Directors

Foamix Pharmaceuticals 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission file number: 001-36621 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) 2 Holzman Street, Weizmann Science Park Rehovot, Israel (Address of princ

Foamix Pharmaceuticals 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission file number: 001-36621 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) 2 Holzman Street, Weizmann Science Park Rehovot, Israel (Address of princ

  FOAMIX PHARMACEUTICALS LTD. 2 Holzman Street, Weizmann Science Park Rehovot, Israel June 7, 2017 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 13, 2017

Exhibit 99.1 ? FOAMIX PHARMACEUTICALS LTD. 2 Holzman Street, Weizmann Science Park Rehovot, Israel June 7, 2017 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 13, 2017 Dear Shareholders: We cordially invite you to attend the annual general meeting of shareholders, or the Meeting, of Foamix Pharmaceuticals Ltd., or the Company, to be held at 3:00 p.m. (Israel time) on Thursday,

Foamix Pharmaceuticals Ltd. FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 13, 2017 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

Exhibit 99.2 Foamix Pharmaceuticals Ltd. PROXY FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 13, 2017 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints each of Dov Tamarkin and Ilan Hadar as the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote, on beh

Foamix Pharmaceuticals 3G/A (Passive Acquisition of More Than 5% of Shares)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Foamix Pharmaceuticals Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) M46135105 (CUSIP Number) April 10, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t

Foamix Pharmaceuticals 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission file number: 001-36621 FOAMIX PHARMACEUTICALS LTD. (Translation of registrant's name into English) 2 Holzman Street, Weizmann Science Park Rehovot, Israel (Address of princi

Foamix Reports First Quarter 2017 Financial Results and Provides Business Update Conference Call and Webcast on Wednesday, May 10, 2017 at 8:30am Eastern / 5:30am Pacific

Exhibit 99.1 News Release May 9, 2017 Foamix Reports First Quarter 2017 Financial Results and Provides Business Update Conference Call and Webcast on Wednesday, May 10, 2017 at 8:30am Eastern / 5:30am Pacific Rehovot, Israel May 9, 2017 ? Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (?Foamix Pharmaceuticals? or the ?Company?), a clinical stage specialty pharmaceutical company focused on developing a

Nasdaq: FOMX FMX101 Topical 4% Minocycline Foam for Moderate-to-Severe AcnePhase 3 Analysis & PlanMay 2017 Phase 3 Pivotal Clinical Studies * Protocol FX2014-04 and Protocol FX2014-05 A Randomized, Double-Blind Study to Compare the Efficacy, Safety a

Exhibit 99.2 Nasdaq: FOMX FMX101 Topical 4% Minocycline Foam for Moderate-to-Severe AcnePhase 3 Analysis & PlanMay 2017 Disclaimer To the extent that statements contained in this presentation are not descriptions of historical facts regarding Foamix, they are forward-looking statements reflecting management?s current beliefs and expectations. Forward-looking statements are subject to known and unk